logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
09/04/2026
Meta: Inspired by Instagram's content rating system for users aged 13 and older, expanding the scope of protection for teenage accounts.
Latest
2 m ago
GF Fund Crude Oil LOF: Trading will be suspended from market opening on April 10, 2026 until 10:30 on the same day, and will resume from 10:30 on April 10, 2026; redemption services for this fund will continue to be processed during the suspension period.
2 m ago
Cheng Lian Branch Cui Dongshu: It is expected that the car market will see positive growth in the second half of the year.
2 m ago
Guotou Silver LOF: It will be suspended from trading starting on April 10, 2026, until 10:30 on the same day. Trading will resume at 10:30 on April 10, 2026. Redemption services for this fund will be conducted as usual during the suspension period.
2 m ago
Crude Oil LOF E Fund: It will be suspended from the market from the market opening on April 10, 2026 until 10:30 on the same day, and resume trading at 10:30 on April 10, 2026; during the suspension period, the redemption business of this fund will be conducted as usual.
3 m ago
Kangchen Pharmaceuticals: KC1036 second-line therapy for late-stage esophageal squamous cell carcinoma pivotal Phase III clinical study approved by CDE.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.